Among all breast cancer patients (n = 4929), the RFS of the high GZMK expression group (n = 2464) was superior to that of the low expression group (n = 2465), with statistical significance (HR = 0.78 [0.71–0.87], P < 0.001) (Figure S4A). Here, GZMK is linked to breast cancer.